Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > KURA Kura Oncology > Detailed Quotes

KURA Kura Oncology

Watchlist
13.820
+0.650+4.94%
Close  01/31 16:00 ET
14.090
+0.270+1.95%
Post Mkt Price 01/31 17:50 ET
High
14.330
Open
14.180
Turnover
8.16M
Low
13.550
Pre Close
13.170
Volume
588.99K
Market Cap
924.52M
P/E(TTM)
Loss
52wk High
19.930
Shares
66.90M
P/E(Static)
Loss
52wk Low
10.410
Float Cap
607.53M
Bid/Ask %
0.00%
Historical High
43.000
Shs Float
43.96M
Volume Ratio
0.74
Historical Low
2.500
Dividend TTM
--
Div Yield TTM
--
P/B
2.20
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.34%
Amplitude
5.92%
Avg Price
13.853
Lot Size
1
Float Cap
607.53M
Bid/Ask %
0.00%
Historical High
43.000
Shs Float
43.96M
Volume Ratio
0.74
Historical Low
2.500
Dividend TTM
--
P/B
2.20
Dividend LFY
--
Turnover Ratio
1.34%
Amplitude
5.92%
Avg Price
13.853
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
CEO: Dr. Troy E. Wilson, PhD, J.D.
Market: NASDAQ
Listing Date: 11/05/2015
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist